Compare ALEMBIC PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA IPCA LABS ALEMBIC PHARMA/
IPCA LABS
 
P/E (TTM) x 15.2 22.9 66.4% View Chart
P/BV x 3.5 4.4 78.7% View Chart
Dividend Yield % 1.1 0.1 1,031.8%  

Financials

 ALEMBIC PHARMA   IPCA LABS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
IPCA LABS
Mar-18
ALEMBIC PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs664695 95.5%   
Low Rs412400 103.1%   
Sales per share (Unadj.) Rs208.7260.2 80.2%  
Earnings per share (Unadj.) Rs31.019.0 163.4%  
Cash flow per share (Unadj.) Rs37.133.1 112.3%  
Dividends per share (Unadj.) Rs5.501.00 550.0%  
Dividend yield (eoy) %1.00.2 559.7%  
Book value per share (Unadj.) Rs144.2213.0 67.7%  
Shares outstanding (eoy) m188.52126.20 149.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.1 122.5%   
Avg P/E ratio x17.428.9 60.1%  
P/CF ratio (eoy) x14.516.6 87.5%  
Price / Book Value ratio x3.72.6 145.2%  
Dividend payout %17.75.3 336.6%   
Avg Mkt Cap Rs m101,46169,120 146.8%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m7,4677,359 101.5%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m39,34732,836 119.8%  
Other income Rs m94418 22.4%   
Total revenues Rs m39,44133,254 118.6%   
Gross profit Rs m8,7364,505 193.9%  
Depreciation Rs m1,1521,777 64.8%   
Interest Rs m184240 76.6%   
Profit before tax Rs m7,4932,905 257.9%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568511 306.7%   
Profit after tax Rs m5,8442,394 244.1%  
Gross profit margin %22.213.7 161.8%  
Effective tax rate %20.917.6 118.9%   
Net profit margin %14.97.3 203.7%  
BALANCE SHEET DATA
Current assets Rs m19,57719,455 100.6%   
Current liabilities Rs m14,89610,076 147.8%   
Net working cap to sales %11.928.6 41.7%  
Current ratio x1.31.9 68.1%  
Inventory Days Days9098 91.7%  
Debtors Days Days4567 67.7%  
Net fixed assets Rs m27,09720,260 133.7%   
Share capital Rs m377252 149.4%   
"Free" reserves Rs m26,81126,633 100.7%   
Net worth Rs m27,18826,886 101.1%   
Long term debt Rs m4,9932,340 213.4%   
Total assets Rs m47,77841,173 116.0%  
Interest coverage x41.713.1 318.4%   
Debt to equity ratio x0.20.1 211.0%  
Sales to assets ratio x0.80.8 103.3%   
Return on assets %12.66.4 197.2%  
Return on equity %21.58.9 241.4%  
Return on capital %23.610.8 219.3%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m19,45315,642 124.4%   
Fx outflow Rs m6,0654,884 124.2%   
Net fx Rs m13,38810,759 124.4%   
CASH FLOW
From Operations Rs m8,1203,411 238.0%  
From Investments Rs m-7,556-1,354 558.1%  
From Financial Activity Rs m590-1,304 -45.3%  
Net Cashflow Rs m1,153753 153.1%  

Share Holding

Indian Promoters % 74.1 45.9 161.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 11.4 25.4%  
FIIs % 9.1 25.3 36.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.4 79.9%  
Shareholders   49,328 36,892 133.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS